The Cysteine Protease Inhibitor, E64d, Reduces Brain Amyloid-β and Improves Memory Deficits in Alzheimer's Disease Animal Models by Inhibiting Cathepsin B, but not BACE1, β-Secretase Activity
Authors:
Open Access
- 9 September 2011
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 26 (2) , 387-408
Abstract
The cysteine protease cathepsin B is a potential drug target for reducing brain amyloid-β (Aβ) and improving memory in Alzheimer's disease (AD), as reduction of cathepsin B in transgenic mice expressing human wild-type amyloid-β protein precursor (AβKeywords
This publication has 84 references indexed in Scilit:
- Genetic cathepsin B deficiency reduces β-amyloid in transgenic mice expressing human wild-type amyloid precursor proteinBiochemical and Biophysical Research Communications, 2009
- Amyloid Precursor Protein Trafficking, Processing, and FunctionJournal of Biological Chemistry, 2008
- Cysteine protease inhibitors effectively reduce in vivo levels of brain β-amyloid related to Alzheimer's diseaseBiological Chemistry, 2007
- Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's diseaseBiological Chemistry, 2005
- Secretases as targets for the treatment of Alzheimer's disease: the prospectsThe Lancet Neurology, 2002
- Primate neurons show different vulnerability to transient ischemia and response to cathepsin inhibitionActa Neuropathologica, 2002
- Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activityNature, 1999
- Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic MiceScience, 1996
- Differential distribution of messenger RNAs for cathepsins B, L and S in adult rat brain: An in situ hybridization studyNeuroscience, 1994
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991